Login to Your Account

CRDAC Not Impressed, Votes No to Cornerstone's Lixivaptan

By Mari Serebrov
Washington Editor

Thursday, September 13, 2012
Questioning the acceptance of serum sodium changes as a surrogate endpoint for hyponatremia drugs, the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) wasn't sold on the clinical efficacy of Cornerstone Therapeutics Inc.'s lixivaptan.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription